Article
Multidisciplinary Sciences
Ping Zhu, Xianglin L. Du, Lu-yu Hwang, David Lairson, Ruosha Li, Yoshua Esquenazi, Jay-Jiguang Zhu
Summary: The optimal time to initiate adjuvant therapy (AT) in elderly patients with glioblastoma (GBM) remains uncertain. Two large-scale datasets from the United States were used to investigate the impact of timing on overall survival (OS) in elderly GBM populations. The study found that initiating AT with a modest delay (27-37 days) or a longer delay (>= 38 days) after craniotomy may be the preferred timing for elderly GBM patients.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Carlen A. Yuen, Marissa Barbaro, Aya Haggiagi
Summary: Management of elderly patients with newly diagnosed glioblastoma (eGBM) presents unique challenges. Although progress has been made in defining the optimal therapeutic approach for these patients, many questions remain unanswered.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Chemistry, Multidisciplinary
Yan Zou, Yibin Wang, Sen Xu, Yanjie Liu, Jinlong Yin, David B. Lovejoy, Meng Zheng, Xing-Jie Liang, Jong Bae Park, Yuri M. Efremov, Ilya Ulasovand, Bingyang Shi
Summary: A new type of GBM-cell membrane camouflaged and pH-sensitive biomimetic nanoparticles have been developed for combined TMZ and CDDP therapy for GBM. The results show that these nanoparticles can efficiently transport drugs across the blood-brain barrier and specifically target GBM, allowing for controlled release at GBM sites and demonstrating potent anti-GBM effects without obvious side effects.
ADVANCED MATERIALS
(2022)
Article
Multidisciplinary Sciences
Loig Vaugier, Loic Ah-Thiane, Maud Aumont, Emmanuel Jouglar, Mario Campone, Camille Colliard, Ludovic Doucet, Jean-Sebastien Frenel, Carole Gourmelon, Marie Robert, Stephane-Andre Martin, Tanguy Riem, Vincent Roualdes, Loic Campion, Augustin Mervoyer
Summary: The study reviewed elderly patients with GBM referred for 6-week CRT, finding that CRT treatment was feasible for this population, even in the case of post-operative neurological disabilities. Age and neurological disabilities did not necessarily affect patient outcomes.
SCIENTIFIC REPORTS
(2021)
Article
Biology
Eric J. Lehrer, Henry Ruiz-Garcia, Anthony D. Nehlsen, Kunal K. Sindhu, Rachel Sarabia Estrada, Gerben R. Borst, Jason P. Sheehan, Alfredo Quinones-Hinojosa, Daniel M. Trifiletti
Summary: In summary, stereotactic radiosurgery (SRS) is a highly effective treatment option for tumors with minimal radiation exposure to healthy tissues. However, the role of preoperative SRS in glioblastoma (GBM) is not well understood due to limited evidence. This review provides an overview of GBM and discusses the potential role of preoperative SRS in its management.
Article
Oncology
Ravi Shridhar, Paige Blinn, Jamie Huston, Kenneth L. Meredith
Summary: This study is the first to show that adjuvant radiation therapy after chemotherapy can significantly improve overall survival in resected high-risk extrahepatic cholangiocarcinoma patients. Further clinical trials are needed to investigate the role of radiation therapy in this population.
Article
Oncology
Lei She, Lin Su, Chao Liu
Summary: The purpose of this study was to evaluate the safety, tolerability, and efficacy of a combination of BEV and re-RT for the treatment of rGBM. The results showed that this combination therapy was safe, tolerable, and effective in rGBM patients. Additionally, gross total resection prior to re-RT and selective concurrent temozolomide further improved patient PFS and OS.
FRONTIERS IN ONCOLOGY
(2022)
Review
Multidisciplinary Sciences
Suely Maymone de Melo, Gustavo Nader Marta, Carolina de Oliveira Cruz Latorraca, Camila Bertini Martins, Orestis Efthimiou, Rachel Riera
Summary: This review found no evidence of a difference between the evaluated HRTs for efficacy and safety.
Article
Oncology
Jingjing Ge, Cheng Li, Fengjun Xue, Shaopei Qi, Zhimeng Gao, Chunjiang Yu, Junping Zhang
Summary: The combination of apatinib and temozolomide shows efficacy in treating recurrent glioblastoma with manageable toxicities. It can be considered as a salvage therapy for patients who have not responded well to other treatments.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Karan L. Chohan, Jason R. Young, Scott Lester, Muhamad Alhaj Moustafa, Allison Rosenthal, Han W. Tun, Bradford S. Hoppe, Patrick B. Johnston, Ivana N. MicaIlef, Thomas M. Habermann, Stephen M. Anse
Summary: This study compared the efficacy of combined modality therapy and chemotherapy-alone in early-stage classical Hodgkin lymphoma (cHL) patients. The results showed that combined modality therapy was beneficial for patients with PET2-positive and unfavorable disease, while chemotherapy-alone achieved comparable outcomes in PET2-negative, favorable, and non-bulky disease patients.
Article
Cell Biology
Inge Compter, Danielle B. P. Eekers, Ann Hoeben, Kasper M. A. Rouschop, Bart Reymen, Linda Ackermans, Jan Beckervordersantforth, Noel J. C. Bauer, Monique M. Anten, Pieter Wesseling, Alida A. Postma, Dirk De Ruysscher, Philippe Lambin
Summary: Treatment with chloroquine in combination with radiotherapy and concurrent temozolomide for newly diagnosed glioblastoma showed favorable toxicity and promising overall survival. The maximum tolerated dose was determined to be 200 mg of chloroquine daily. Further clinical studies are supported by these results.
Article
Medicine, Research & Experimental
Le Huang, Huixia He, Ke Wang, Xuqian Ma, Xin Chen, Wenxin Chen, Xuan Wang, Xiaobing Jiang, Mingqian Feng
Summary: This study aims to explore the efficacy of EGFRvIII-targeted immunotoxin combined with TMZ or T cell-engaged bispecific antibody in the treatment of GBM. The results showed that this combination therapy had potent anti-tumor effects in multiple mouse models.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Medicine, Research & Experimental
Maoyuan Sun, Ning Huang, Yihao Tao, Rong Wen, Guanjian Zhao, Xiang Zhang, Zongyi Xie, Yuan Cheng, Jinning Mao, Guodong Liu
Summary: This is a double-blind randomized clinical trial designed to investigate the therapeutic effect of the combination of levetiracetam and temozolomide in the treatment of glioblastoma. The results of this trial are expected to provide high-level evidence regarding the clinical benefits of this combination therapy.
Article
Pharmacology & Pharmacy
Riccardo Serra, Antonella Mangraviti, Noah L. Gorelick, Tovi Shapira-Furman, Safwan Alomari, Arba Cecia, Namrata Darjee, Henry Brem, Yakir Rottenberg, Abraham J. Domb, Betty Tyler
Summary: This study tested a novel polymeric matrix that gradually releases ACF at the tumor bed while combining it with TMZ and XRT. The combination therapy of ACF, TMZ, and XRT reduced cell viability and induced apoptosis in glioma cells. The release of ACF was measured in vitro and in vivo, and the efficacy was established in an in vivo gliosarcoma model, showing improved median survival and long-term survival.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2022)
Article
Oncology
Leon Emanuel Schnoeller, Valerie Albrecht, Nikko Brix, Alexander Edward Nieto, Daniel Felix Fleischmann, Maximilian Niyazi, Julia Hess, Claus Belka, Kristian Unger, Kirsten Lauber, Michael Orth
Summary: This study integrated clonogenic survival data with mRNA expression data of DNA damage response regulators in human glioblastoma cell lines to identify potential markers of inherent therapy resistance and vulnerabilities for targeted sensitization. Results showed that inhibition of ATR can enhance the radiosensitivity of glioblastoma cells, while inhibition of LIG4 had no significant impact. Inhibition of ATM may also sensitize glioblastoma cells to temozolomide treatment in cases of low MGMT expression.
RADIATION ONCOLOGY
(2022)
Article
Oncology
Nimish A. Mohile, Hans Messersmith, Na Tosha Gatson, Andreas F. Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson, James Perry, Jana Portnow, David Schiff, Anne Shannon, Helen A. Shih, Roy Strowd, Martin van den Bent, Mateo Ziu, Jaishri Blakeley
Summary: This article provides guidance on the therapy for diffuse astrocytic and oligodendroglial tumors in adults. The recommendations are based on a systematic literature review and offer specific treatment options for different tumor grades, with reasonable alternatives. The article also provides treatment suggestions for specific patient populations.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Isabelle M. Germano, Mateo Ziu, Patrick Wen, D. Ryan Ormond, Jeffrey J. Olson
Summary: This article provides recommendations for the treatment of adult patients with pGBM, including the use of TMZ, nitrosourea, platinum compounds, topoisomerase inhibitors, TTF, and oncolytic virotherapy.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Review
Oncology
Evan Winograd, Isabelle Germano, Patrick Wen, Jeffrey J. Olson, D. Ryan Ormond
Summary: The recommendations provided apply to adults with progressive GBM who have undergone standard primary treatment, suggesting the use of bevacizumab for improved disease control. There is insufficient evidence to support the benefit or harm of combining bevacizumab with cytotoxic or targeted therapies in progressive glioblastoma.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Nimish A. Mohile, Hans Messersmith, Na Tosha Gatson, Andreas F. Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson, James Perry, Jana Portnow, David Schiff, Anne Shannon, Helen A. Shih, Roy Strowd, Martin van den Bent, Mateo Ziu, Jaishri Blakeley
Summary: This article provides guidance for therapy of diffuse astrocytic and oligodendroglial tumors in adults. Based on a systematic review of literature, the article provides recommendations for different tumor types and grades, including radiation therapy, chemotherapy, and other treatment options.
Article
Clinical Neurology
Philip D. Tatman, Tadeusz H. Wroblewski, Anthony R. Fringuello, Samuel R. Scherer, William B. Foreman, Denise M. Damek, Kevin O. Lillehei, Randy L. Jensen, A. Samy Youssef, D. Ryan Ormond, Michael W. Graner
Summary: The study found that decitabine can reduce cell viability in meningiomas, with this effect primarily driven by a subset of tumors. Meningiomas of different sexes, grades, and treatment histories may all respond positively to this treatment.
WORLD NEUROSURGERY
(2022)
Article
Biochemistry & Molecular Biology
Frederick S. Varn, Kevin C. Johnson, Jan Martinek, Jason T. Huse, MacLean P. Nasrallah, Pieter Wesseling, Lee A. D. Cooper, Tathiane M. Malta, Taylor E. Wade, Thais S. Sabedot, Daniel Brat, Peter Gould, Adelheid Woehrer, Kenneth Aldape, Azzam Ismail, Santhosh K. Sivajothi, Floris P. Barthel, Hoon Kim, Emre Kocakavuk, Nazia Ahmed, Kieron White, Indrani Datta, Hyo-Eun Moon, Steven Pollock, Christine Goldfarb, Ga-Hyun Lee, Luciano Garofano, Kevin J. Anderson, Djamel Nehar-Belaid, Jill S. Barnholtz-Sloan, Spyridon Bakas, Annette T. Byrne, Fulvio D'Angelo, Hui K. Gan, Mustafa Khasraw, Simona Migliozzi, D. Ryan Ormond, Sun Ha Paek, Erwin G. Van Meir, Annemiek M. E. Walenkamp, Colin Watts, Tobias Weiss, Michael Weller, Karolina Palucka, Lucy F. Stead, Laila M. Poisson, Houtan Noushmehr, Antonio Iavarone, Roel G. W. Verhaak
Summary: This study analyzed RNA and DNA sequencing data from tumor pairs of patients with IDH-wild-type and IDH-mutant glioma, and identified the factors driving therapy resistance and recurrence. The results showed that IDH status, histological features, somatic alterations, and microenvironment interactions play important roles in glioma recurrence. Furthermore, specific cellular and genetic changes were associated with tumor growth, invasion, and neuronal interactions, providing potential targets for altering disease progression.
Article
Oncology
Jay C. Shiao, Douglas Holt, Colton Ladbury, Dexiang Gao, Bernard Jones, Sana D. Karam, Arya Amini
Summary: CCRT showed improved OS for HPV-positive and HPV-negative T3N0 OPSCC. RT alone demonstrated similar OS to CCRT for both HPV-negative and HPV-positive T1-T2N0 OPSCC.
Article
Clinical Neurology
Philip D. Tatman, Tadeusz H. Wroblewski, Anthony R. Fringuello, Samuel R. Scherer, William B. Foreman, Denise M. Damek, A. Samy Youssef, Kevin O. Lillehei, Randy L. Jensen, Michael W. Graner, D. Ryan Ormond
Summary: Epigenetics may be more accurate than histopathology in predicting treatment sensitivity and clinical course for patients with meningiomas. In this study, the researchers investigated the efficacy of targeting epigenetic mechanisms for treating meningiomas and found that epigenetic inhibition could be a potential therapeutic development for these tumors.
JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE
(2023)
Article
Clinical Neurology
Xavier Boumaza, Baptiste Bonneau, Damien Roos-Weil, Carmela Pinnetti, Sebastian Rauer, Louisa Nitsch, Arnaud Del Bello, Ilijas Jelcic, Kurt-Wolfram Suehs, Jacques Gasnault, Yasemin Goreci, Oliver Grauer, Sharmilee Gnanapavan, Rebecca Wicklein, Nicolas Lambert, Thomas Perpoint, Martijn Beudel, David Clifford, Agnes Sommet, Irene Cortese, Guillaume Martin-Blondel
Summary: This study aimed to evaluate the real-world effectiveness of immune checkpoint inhibitors in the treatment of patients with progressive multifocal leukoencephalopathy (PML). Retrospective data from 79 PML patients who received immune checkpoint inhibitors were analyzed, and the results showed that mortality remained high and the development of inflammatory features or PML-IRIS was commonly observed. The study highlights the importance of personalized use of immune checkpoint inhibitors for PML patients.
ANNALS OF NEUROLOGY
(2023)
Article
Biochemistry & Molecular Biology
Wenbo Zhou, Daniel Lovasz, Zoe Zizzo, Qianbin He, Christina Coughlan, Robert G. Kowalski, Peter G. E. Kennedy, Arin N. Graner, Kevin O. Lillehei, D. Ryan Ormond, A. Samy Youssef, Michael W. Graner, Xiaoli Yu
Summary: Glioblastoma extracellular vesicles (EVs) have dose-dependent cytotoxic effects on neurons and can induce IgG-mediated neuronal apoptosis and necrosis. GBM plasma EVs are smaller in size and their size does not correlate with concentration.
Article
Multidisciplinary Sciences
Sarthak Pati, Ujjwal Baid, Brandon Edwards, Micah Sheller, Shih-Han Wang, G. Anthony Reina, Patrick Foley, Alexey Gruzdev, Deepthi Karkada, Christos Davatzikos, Chiharu Sako, Satyam Ghodasara, Michel Bilello, Suyash Mohan, Philipp Vollmuth, Gianluca Brugnara, Chandrakanth J. Preetha, Felix Sahm, Klaus Maier-Hein, Maximilian Zenk, Martin Bendszus, Wolfgang Wick, Evan Calabrese, Jeffrey Rudie, Javier Villanueva-Meyer, Soonmee Cha, Madhura Ingalhalikar, Manali Jadhav, Umang Pandey, Jitender Saini, John Garrett, Matthew Larson, Robert Jeraj, Stuart Currie, Russell Frood, Kavi Fatania, Raymond Y. Huang, Ken Chang, Carmen Balana, Jaume Capellades, Josep Puig, Johannes Trenkler, Josef Pichler, Georg Necker, Andreas Haunschmidt, Stephan Meckel, Gaurav Shukla, Spencer Liem, Gregory S. Alexander, Joseph Lombardo, Joshua D. Palmer, Adam E. Flanders, Adam P. Dicker, Haris I. Sair, Craig K. Jones, Archana Venkataraman, Meirui Jiang, Tiffany Y. So, Cheng Chen, Pheng Ann Heng, Qi Dou, Michal Kozubek, Filip Lux, Jan Michalek, Petr Matula, Milos Kerkovsky, Tereza Koprivova, Marek Dostal, Vaclav Vybihal, Michael A. Vogelbaum, J. Ross Mitchell, Joaquim Farinhas, Joseph A. Maldjian, Chandan Ganesh Bangalore Yogananda, Marco C. Pinho, Divya Reddy, James Holcomb, Benjamin C. Wagner, Benjamin M. Ellingson, Timothy F. Cloughesy, Catalina Raymond, Talia Oughourlian, Akifumi Hagiwara, Chencai Wang, Minh-Son To, Sargam Bhardwaj, Chee Chong, Marc Agzarian, Alexandre Xavier Falcao, Samuel B. Martins, Bernardo C. A. Teixeira, Flavia Sprenger, David Menotti, Diego R. Lucio, Pamela La Montagne, Daniel Marcus, Benedikt Wiestler, Florian Kofler, Ivan Ezhov, Marie Metz, Rajan Jain, Matthew Lee, Yvonne W. Lui, Richard McKinley, Johannes Slotboom, Piotr Radojewski, Raphael Meier, Roland Wiest, Derrick Murcia, Eric Fu, Rourke Haas, John Thompson, David Ryan Ormond, Chaitra Badve, Andrew E. Sloan, Vachan Vadmal, Kristin Waite, Rivka R. Colen, Linmin Pei, Murat Ak, Ashok Srinivasan, J. Rajiv Bapuraj, Arvind Rao, Nicholas Wang, Ota Yoshiaki, Toshio Moritani, Sevcan Turk, Joonsang Lee, Snehal Prabhudesai, Fanny Moron, Jacob Mandel, Konstantinos Kamnitsas, Glocker Ben, Luke V. M. Dixon, Matthew Williams, Peter Zampakis, Vasileios Panagiotopoulos, Panagiotis Tsiganos, Sotiris Alexiou, Ilias Haliassos, Evangelia I. Zacharaki, Konstantinos Moustakas, Christina Kalogeropoulou, Dimitrios M. Kardamakis, Yoon Seong Choi, Seung-Koo Lee, Jong Hee Chang, Sung Soo Ahn, Bing Luo, Laila Poisson, Ning Wen, Pallavi Tiwari, Ruchika Verma, Rohan Bareja, Ipsa Yadav, Jonathan Chen, Neeraj Kumar, Marion Smits, Sebastian R. van der Voort, Ahmed Alafandi, Fatih Incekara, Maarten M. J. Wijnenga, Georgios Kapsas, Renske Gahrmann, Joost W. Schouten, Hendrikus J. Dubbink, Arnaud J. P. E. Vincent, Martin J. van den Bent, Pim J. French, Stefan Klein, Yading Yuan, Sonam Sharma, Tzu-Chi Tseng, Saba Adabi, Simone P. Niclou, Olivier Keunen, Ann-Christin Hau, Martin Vallieres, David Fortin, Martin Lepage, Bennett Landman, Karthik Ramadass, Kaiwen Xu, Silky Chotai, Lola B. Chambless, Akshitkumar Mistry, Reid C. Thompson, Yuriy Gusev, Krithika Bhuvaneshwar, Anousheh Sayah, Camelia Bencheqroun, Anas Belouali, Subha Madhavan, Thomas C. Booth, Alysha Chelliah, Marc Modat, Haris Shuaib, Carmen Dragos, Aly Abayazeed, Kenneth Kolodziej, Michael Hill, Ahmed Abbassy, Shady Gamal, Mahmoud Mekhaimar, Mohamed Qayati, Mauricio Reyes, Ji Eun Park, Jihye Yun, Ho Sung Kim, Abhishek Mahajan, Mark Muzi, Sean Benson, Regina G. H. Beets-Tan, Jonas Teuwen, Alejandro Herrera-Trujillo, Maria Trujillo, William Escobar, Ana Abello, Jose Bernal, Jhon Gomez, Joseph Choi, Stephen Baek, Yusung Kim, Heba Ismael, Bryan Allen, John M. Buatti, Aikaterini Kotrotsou, Hongwei Li, Tobias Weiss, Michael Weller, Andrea Bink, Bertrand Pouymayou, Hassan F. Shaykh, Joel Saltz, Prateek Prasanna, Sampurna Shrestha, Kartik M. Mani, David Payne, Tahsin Kurc, Enrique Pelaez, Heydy Franco-Maldonado, Francis Loayza, Sebastian Quevedo, Pamela Guevara, Esteban Torche, Cristobal Mendoza, Franco Vera, Elvis Rios, Eduardo Lopez, Sergio A. Velastin, Godwin Ogbole, Mayowa Soneye, Dotun Oyekunle, Olubunmi Odafe-Oyibotha, Babatunde Osobu, Mustapha Shu'aibu, Adeleye Dorcas, Farouk Dako, Amber L. Simpson, Mohammad Hamghalam, Jacob J. Peoples, Ricky Hu, Anh Tran, Danielle Cutler, Fabio Y. Moraes, Michael A. Boss, James Gimpel, Deepak Kattil Veettil, Kendall Schmidt, Brian Bialecki, Sailaja Marella, Cynthia Price, Lisa Cimino, Charles Apgar, Prashant Shah, Bjoern Menze, Jill S. Barnholtz-Sloan, Jason Martin, Spyridon Bakas
Summary: This study presents the largest federated learning (FL) research to-date, involving data from 71 sites across 6 continents. By only sharing numerical model updates, the study successfully generates an automatic tumor boundary detector for glioblastoma and demonstrates significant improvements in tumor delineation.
NATURE COMMUNICATIONS
(2022)
Article
Hematology
Kevin A. A. David, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek, Jordan Carter, Adam Zayac, Myung Sun Kim, Nishitha Reddy, Douglas Ney, Alma Habib, Christopher Strouse, Jerome Graber, Veronika Bachanova, Sidra Salman, Jean Alyxa Vendiola, Nasheed Hossain, Mazie Tsang, Ajay Major, David A. A. Bond, Prashasti Agrawal, Angel Mier-Hicks, Pallawi Torka, Priya Rajakumar, Parameswaran Venugopal, Stephanie Berg, Michael Glantz, Samuel A. A. Goldlust, Matthew Folstad, Pallavi Kumar, Thomas A. A. Ollila, Johnny Cai, Stephen Spurgeon, Alex Sieg, Joseph Cleveland, Julie Chang, Narendranath Epperla, Reem Karmali, Seema Naik, Peter Martin, Sonali M. M. Smith, James Rubenstein, Brad Kahl, Andrew M. M. Evens
Summary: This retrospective analysis examined the outcomes and prognostic factors of 539 newly-diagnosed PCNSL patients aged 60 years and older from 20 U.S. academic centers. The study found that induction regimens using high-dose methotrexate (HD-MTX) combined with rituximab, as well as maintenance therapy, optimized the outcomes for older PCNSL patients. Additionally, several factors including age, hypoalbuminemia, high CIRS-G score, and ECOG performance status were associated with inferior outcomes.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Prashasti Agrawal, Kevin A. A. David, Zhengming Chen, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek, Jordan Carter, Adam Zayac, Myung Sun Kim, Nishitha Reddy, Douglas Ney, Alma Habib, Christopher Strouse, Jerome Graber, Veronika Bachanova, Sidra Salman, Jean A. A. Vendiola, Nasheed Hossain, Mazie Tsang, Ajay Major, Maher K. K. Gandhi, Colm Keane, David A. A. Bond, Matthew Folstad, Julie Chang, Angel Mier-Hicks, Pallawi Torka, Priya Rajakumar, Parameswaran Venugopal, Stephanie Berg, Michael Glantz, Samuel A. A. Goldlust, Rahul Matnani, Pallavi Kumar, Thomas A. A. Ollila, Johnny Cai, Stephen E. E. Spurgeon, Alex G. G. Sieg, Joseph Cleveland, Narendranath Epperla, Reem Karmali, Seema Naik, Sonali M. M. Smith, James L. L. Rubenstein, Brad S. S. Kahl, Amy Chadburn, Andrew M. M. Evens, Peter Martin
Summary: The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. The study found that 11.7% of CNSL patients aged ≥ 60 had EBV + tumors, mainly solid organ transplant-related post-transplant lymphoproliferative disorders (PTLD). EBV positive tumors were associated with younger age, solid organ transplant or autoimmune disease, and immunosuppressive treatment. Furthermore, EBV + PTLD had a shorter median overall survival compared to EBV + non-PTLD and EBV-negative patients.
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Nader Ghassemi, Richard Castillo, Edward Castillo, Bernard L. Jones, Moyed Miften, Brian Kavanagh, Maria Werner-Wasik, Ryan Miller, Julie A. Barta, Inga Grills, Benjamin E. Leiby, Thomas Guerrero, Chad G. Rusthoven, Yevgeniy Vinogradskiy
Summary: This study evaluated the factors predicting pulmonary function changes in patients receiving functional avoidance radiotherapy. The data showed that lung dose-function metrics can predict pulmonary function changes, proving the importance of reducing dose to functional lung regions and providing guidance for future clinical trials.
RADIOTHERAPY AND ONCOLOGY
(2023)
Meeting Abstract
Oncology
Jiayi Huang, Feng Gao, Joshua Shimony, Tanner Michael Johanns, Megan Mantica, Timothy Robin Gershon, Douglas Edward Ney, Tolga Tuncer Joe Sammy Mendez, Howard Streicher, Jian Li Campian
JOURNAL OF CLINICAL ONCOLOGY
(2022)